Antibody-conjugated lipid nanoparticles designed for precise cell targeting, controlled payload presentation, and translationally relevant formulation development.
Antibody conjugated lipid nanoparticles combine the payload versatility of lipid nanoparticles for drug delivery with the binding specificity of antibodies or antibody fragments, creating targeted systems for cell-selective delivery of nucleic acids, proteins, peptides, and small molecules. These constructs are increasingly explored when passive biodistribution is not sufficient and when receptor-mediated uptake, improved tissue selectivity, and reduced off-target exposure are central to project goals. However, successful development requires more than simple surface decoration. Ligand orientation, conjugation density, linker stability, particle size, PEG architecture, and payload compatibility all influence biological performance and manufacturability. BOC Sciences provides integrated antibody-LNP development services spanning conjugation strategy design, surface engineering, formulation screening, physicochemical characterization, and application-focused optimization to help researchers build robust targeted lipid nanoparticle systems for advanced pharmaceutical and biotechnology programs.
Structure of Antibody-Modified LNPOur service framework is built for research teams seeking targeted LNP systems with clearly defined surface functionality, reproducible formulation behavior, and application-oriented performance evaluation.
We design antibody-conjugated lipid nanoparticles based on target biology, payload type, and intended delivery route, ensuring that the ligand strategy supports both target recognition and nanoparticle integrity.
We support multiple conjugation routes for anchoring antibodies or antibody fragments onto LNP surfaces while preserving ligand function and minimizing destabilization of the carrier.
Antibody decoration must be integrated into a robust lipid nanoparticle formulation workflow so that targeting performance does not come at the expense of encapsulation, stability, or scalability.
We tailor antibody-LNP systems for multiple therapeutic modalities, including nucleic acids, proteins, peptides, and hydrophobic cargoes requiring surface targeting and protected delivery.
Antibody-conjugated LNPs require more than standard particle analysis. We characterize both the carrier core and the functionalized surface to generate a complete quality profile.
We optimize antibody-LNP constructs against key functional bottlenecks that often limit real-world utility in targeted nanomedicine programs.
We support the development of diverse antibody-conjugated lipid nanoparticle formats tailored to different targeting strategies, payload classes, and biological applications. Our services cover both conventional antibody-decorated LNPs and more specialized constructs designed for improved selectivity, cellular uptake, and functional delivery performance.
From conjugation strategy to formulation optimization, we help transform targeted delivery concepts into experimentally robust lipid nanoparticle platforms.
Antibody-conjugated lipid nanoparticles are adaptable to a wide range of therapeutic payloads and research models where selective cellular interaction is required. We align conjugation strategy, surface chemistry, and formulation composition with the needs of each modality.
| Payload / Project Type | Development Focus |
|---|---|
| mRNA-Loaded Antibody-LNPs | Designed for selective transfection where receptor-mediated uptake can improve expression in hard-to-reach cell populations. |
| siRNA and Other Oligonucleotide Systems | Built for targeted gene silencing applications requiring enhanced uptake, intracellular delivery, and reduced nonspecific exposure. |
| Protein and Peptide Delivery | Suitable for programs that require protective encapsulation with biologically directed cell entry. |
| Small Molecule or Combination Payloads | Applicable to targeted delivery concepts where payload retention and surface ligand presentation must be co-optimized. |
| Cell-Type Targeting Studies | Useful for oncology, immunology, inflammatory disease, and tissue-selective delivery research programs exploring receptor-guided nanoparticle uptake. |
| Custom Surface-Engineered Constructs | Supported through project-specific lipid modification and custom synthesis routes for specialized targeting architectures. |
Antibody-LNP programs often fail because targeting concepts are added late or evaluated without sufficient control of nanoparticle surface chemistry. Our workflows are designed to solve the most common technical barriers.
✔ Loss of Antibody Activity After Coupling
Random surface attachment can impair antigen recognition. We optimize conjugation routes and reaction conditions to better preserve ligand accessibility and binding function.
✔ Poor Control of Ligand Density
Too little antibody may not improve targeting, while too much can promote aggregation or hinder stealth behavior. We screen and characterize density-dependent effects to define practical operating windows.
✔ Instability After Surface Functionalization
Antibody addition can alter size distribution, charge, and payload retention. We compare pre- and post-conjugation properties to identify destabilizing variables early.
✔ Steric Shielding by PEG Layers
Surface antibodies may become partially masked by PEG-lipids or unfavorable linker geometry. We optimize spacer and anchor design to improve receptor accessibility.
✔ Inconsistent Targeted Uptake Results
Variable data often arise from incomplete surface characterization rather than target biology alone. Our workflow integrates analytical confirmation with functional testing logic.
✔ Payload-Core-Surface Trade-Offs
A targeted LNP must maintain encapsulation, controlled size, and effective surface presentation simultaneously. We optimize these parameters together rather than in isolation.
We evaluate target biology, payload class, desired delivery profile, and antibody format to define an appropriate surface-engineering strategy.
LNP composition, functional lipid content, conjugation chemistry, and purification approach are optimized in parallel for targeted construct generation.
We assess particle quality, surface functionalization, and payload retention, then compare targeted and control formulations in fit-for-purpose screening workflows.
Final recommendations are supported by structured datasets covering formulation parameters, conjugation outcomes, and candidate-specific performance observations.
Challenge: A client aimed to develop an in vivo mRNA delivery system for CAR-T cell engineering, but found that standard ionizable LNPs were almost exclusively sequestered by the liver through ApoE-mediated uptake, with less than 0.1% reaching the circulating T-cell population.
Diagnosis: The natural hepatotropism of LNPs necessitates an active redirection mechanism. The key challenge was to conjugate a large monoclonal antibody (mAb) without causing particle aggregation or impairing the endosomal escape machinery of the LNP.
Solution: We designed a site-specific anti-CD3-conjugated LNP. To ensure orientation-controlled binding, we synthesized a specialized DSPE-PEG-maleimide linker. Instead of random lysine conjugation, we utilized a mild reduction protocol to expose hinge-region thiols on the antibody, enabling covalent attachment to the LNP surface while preserving the affinity of the Fab region. We optimized the Ab-to-lipid ratio via microfluidic post-insertion to maintain a narrow polydispersity index (PDI < 0.15). Surface density was precisely tuned to provide sufficient avidity for T-cell receptors without triggering premature systemic cytokine release.
Result: The immuno-LNP achieved a 25-fold increase in mRNA expression in splenic T cells and successfully induced transient CAR expression in vivo, thereby bypassing liver sequestration.
Challenge: A research team faced high off-target toxicity in bone marrow and spleen when using LNPs to deliver cytotoxic agents to HER2+ breast cancer cells, as the particles were rapidly scavenged by the mononuclear phagocyte system (MPS).
Diagnosis: Full-length IgG antibodies on the LNP surface often increase the hydrodynamic diameter and interact with Fc receptors on macrophages, paradoxically accelerating clearance despite the targeting intent.
Solution: Our team proposed an anti-HER2 scFv (single-chain variable fragment) conjugation strategy. By utilizing scFv instead of full-length IgG, we significantly reduced the protein corona footprint and eliminated Fc-mediated phagocytosis. We employed a one-pot click chemistry approach based on DBCO-azide chemistry for highly efficient conjugation during the LNP assembly phase. We also introduced a long-chain PEG spacer (MW ≈ 3400) to elevate the scFv above the dense PEG shield, ensuring that the targeting ligand remained accessible for binding to HER2 receptors on the tumor cell surface.
Result: The scFv-LNP formulation demonstrated a 5-fold increase in tumor accumulation and reduced splenic uptake by 60%, significantly widening the therapeutic window for the cytotoxic payload.
Integrated Surface EngineeringWe address antibody selection, conjugation chemistry, lipid composition, and analytical verification as one connected development problem.
Application-Oriented Formulation LogicOur workflows are tailored to the payload, target cell biology, and surface engineering challenges associated with targeted LNP programs.
Flexible Conjugation StrategiesWe support multiple ligand attachment routes and help select practical chemistries for robust antibody presentation.
Comprehensive CharacterizationWe examine the nanoparticle core, the modified surface, and the impact of conjugation on payload integrity to support better-informed decisions.
Targeting-Focused OptimizationRather than treating the antibody as an add-on, we optimize the full system to improve the likelihood of meaningful targeted delivery outcomes.
The core advantages of Antibody-Conjugated Lipid Nanoparticles (Antibody-Conjugated LNPs) lie in their ability to combine the targeting and recognition capability of antibodies with the delivery and loading capacity of lipid nanoparticles. This enables improved accumulation of active molecules in specific cells or tissues, reduced distribution to off-target sites, and expanded design flexibility for drug administration in pharmaceutical development. For teams developing nucleic acid therapeutics, small molecules, proteins, or multi-component payloads, these systems are particularly well suited to addressing two key challenges: how to improve delivery selectivity and how to enhance functional integration within the system. As a result, they have attracted growing attention in the development of targeted delivery platforms.
Selecting suitable antibodies or ligands for LNP conjugation generally requires a comprehensive evaluation across multiple dimensions, including target expression characteristics, internalization capability, binding specificity, retention of activity after conjugation, and compatibility with the lipid system. For drug development clients, the key consideration is not only whether binding can occur, but whether the conjugated antibody or ligand can still stably recognize the target while preserving the overall performance of the nanoparticle system. BOC Sciences can provide support in antibody screening, conjugation strategy design, and carrier compatibility assessment, helping clients reduce trial-and-error costs at an early stage and build a more solid technical foundation for subsequent targeted delivery research.
Antibody-Conjugated LNPs have strong platform adaptability and are commonly used in delivery studies involving nucleic acid therapeutics, oligonucleotides, siRNA, mRNA, peptides, proteins, and certain hydrophobic small molecules. Their value lies not in serving a single payload category, but in enabling more precise cellular targeting through surface antibodies, thereby improving the development feasibility of complex therapeutic formats. For projects that need to balance protection, drug-loading capacity, and targeting capability, these delivery systems are often more likely to support differentiated solutions, which is why they have become a high-frequency topic in precision delivery development.
Yes, and this is one of the most closely watched issues during development. Antibody conjugation may affect LNP particle size distribution, surface charge, steric hindrance, degree of binding-site exposure, and structural integrity during storage. If poorly designed, it may also reduce drug-loading efficiency or impair targeting performance. Therefore, the key to success lies in the coordinated optimization of conjugation chemistry, lipid composition, and antibody orientation, rather than overemphasizing any single parameter. BOC Sciences has systematic service capabilities in lipid nanoparticle design, surface modification, and conjugation process development, helping clients more efficiently balance stability and functionality.
Pharmaceutical and biotechnology companies value antibody-modified LNP platforms mainly because they offer both modular development potential and multi-project scalability. Once a core platform has been established, new candidate directions can be rapidly expanded by switching antibodies, adjusting lipid composition, or adapting to different payloads, thereby improving R&D efficiency and enhancing the reusability of technical assets. For teams aiming to build differentiated delivery capabilities, this is not merely a formulation issue, but a platform strategy issue. BOC Sciences can provide integrated support ranging from custom lipid materials to the development of conjugated nanodelivery systems, helping projects move more smoothly into advanced research stages.
